Last $2.74 USD
Change Today +0.04 / 1.48%
Volume 359.8K
ASTM On Other Exchanges
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

aastrom biosciences inc (ASTM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/21/14 - $7.00
52 Week Low
09/16/14 - $2.58
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

aastrom biosciences inc (ASTM) Related Businessweek News

No Related Businessweek News Found

aastrom biosciences inc (ASTM) Details

Aastrom Biosciences, Inc., a clinical-stage biotechnology company, focuses on the development of cell therapies for use in the treatment of severe chronic ischemic cardiovascular diseases. The company is developing a manufacturing technology platform, the Aastrom Replicell System, which enables the expansion of a various cell types, including the production of multicellular therapies expanded from an adult patient’s own bone marrow that can be delivered directly to damaged tissues. Its lead product candidate include ixmyelocel-T, to treat patients with severe chronic ischemic cardiovascular diseases, such as advanced heart failure due to dilated cardiomyopathy, the third leading cause of heart failure, and critical limb ischemia. The company was founded in 1989 and is headquartered in Ann Arbor, Michigan.

190 Employees
Last Reported Date: 08/14/14
Founded in 1989

aastrom biosciences inc (ASTM) Top Compensated Officers

Chief Executive Officer, President, Treasurer...
Total Annual Compensation: $358.3K
Chief Operating Officer
Total Annual Compensation: $320.0K
Total Annual Compensation: $79.8K
Compensation as of Fiscal Year 2013.

aastrom biosciences inc (ASTM) Key Developments

Aastrom Biosciences Mulls Acquisitions

Aastrom Biosciences, Inc. (NasdaqCM:ASTM), which is planning for a $13.7 million share sale, is looking for acquisitions. It may also use a portion of the net proceeds to acquire or invest in complementary cell therapy and regenerative medicine businesses, technologies, products or assets.

Aastrom Biosciences, Inc. Announces Results from the Phase 2a Clinical Studies of Ixmyelocel-T

Aastrom Biosciences, Inc. announced that results from the company's Phase 2a clinical studies of ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM) were published in the peer-reviewed journal Circulation Research. In an article entitled 'Safety and Efficacy of Ixmyelocel-T: An Expanded, Autologous Multi-Cellular Therapy, in Dilated Cardiomyopathy,' results showed that treatment with ixmyelocel-T reduced the incidence of major adverse cardiovascular events (MACE) in patients with ischemic DCM. In two separate open-label studies, a total of 61 patients were randomized and 59 were treated or received standard of care. The combined results among ischemic DCM patients demonstrated that patients treated with ixmyelocel-T experienced fewer MACE events during follow up compared to control patients. Heart failure (HF) exacerbation was the most common MACE. Relative to the control patients, ischemic DCM patients treated with ixmyelocel-T also experienced an improvement in symptoms as measured by the New York Heart Association classification system, a six-minute walk test, and the Minnesota Living with Heart Failure Questionnaire. Similar benefits were not observed in the non-ischemic population.

Aastrom Biosciences, Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014

Aastrom Biosciences, Inc. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $4,432,000 against $3,000 a year ago. Loss from operations was $8,522,000 against $5,234,000 a year ago. Net loss was $4,638,000 or $0.94 per basic and diluted share against $4,889,000 or $2.72 per basic and diluted share a year ago. For the six months, the company reported total revenues of $4,432,000 against $11,000 a year ago. Loss from operations was $13,166,000 against $12,399,000 a year ago. Net loss was $10,633,000 or $2.18 per basic and diluted share against $10,433,000 or $5.75 per basic and diluted share a year ago. For the six months ended June 30, 2014, cash used for operations was $10.7 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ASTM:US $2.74 USD +0.04

ASTM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $0.37 USD -0.0005
BioTime Inc $3.79 USD +0.24
IntelliCell BioSciences Inc $0.0014 USD 0.0001
Neuralstem Inc $3.32 USD +0.06
ReNeuron Group PLC 3.58 GBp +0.125
View Industry Companies

Industry Analysis


Industry Average

Valuation ASTM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AASTROM BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at